Our Team
Rooted in Science. Driven by Purpose.
At Hummsa, we believe that solving some of the world’s most complex health challenges starts with assembling the right minds. Our team blends visionary leadership with deep scientific expertise, united by a mission to reimagine chronic disease care for a healthier, longer-living world.
Leadership Team
Our leadership team combines scientific insight and strategic vision to drive Hummsa’s mission of transforming chronic disease care from the ground up.
Harshad Lalwani is the founder and CEO of Hummsa Biotech, developing novel therapeutics for metabolic disorders that shape human longevity.
Harshad Lalwani is the founder and CEO of Hummsa Biotech, developing novel therapeutics for metabolic disorders that shape human longevity.
He leads the company's mission to translate cutting-edge research into life-extending treatments through rigorous scientific validation and first-principles thinking.
Operating from emerging markets with global ambitions, Harshad combines strategic business acumen with deep scientific understanding. His leadership focuses on sustainable innovation, balancing commercial viability with meaningful impact in addressing age-related metabolic diseases.
His leadership combines experience from capital-intensive industries like real estate and defence with a deep focus on scientific rigor and strategic clarity. Under his direction, Hummsa is advancing a novel pipeline targeting chronic diseases that impact global longevity and quality of life.A lifelong athlete and student of both ancient strategy and modern systems, Harshad leads with intensity, discipline, and long-game focus.
His philosophy?
Build lean. Think deep. Deliver science that lasts.
Scientific Advisors
Our Scientific Advisory Board comprises internationally recognised experts in chronic metabolic diseases, drug development, and systems biology. Their insights guide our research, pipeline development, and clinical strategy.
Professor of Medicine, Harvard Medical School; Senior Investigator & Co-Head, Section on Islet & Regenerative Biology, Joslin Diabetes Center
Dr. Rohit N. Kulkarni is an internationally recognised scientist in diabetes and metabolism research, with pioneering expertise in beta cell biology, GLP-1 therapeutics, and metabolic disease pathways.
The significance of his work lies in enhancing functional beta cell numbers and developing transformative approaches for treating diabetes and obesity—research directly aligned with Hummsa Biotech's therapeutic pipeline.
His distinguished scientific contributions have earned prestigious recognition, including the Endocrine Society's Ernst Oppenheimer Award and the EASD Albert Renold Prize. As an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the American Association for the Advancement of Science, he represents the highest calibre of scientific excellence.
Currently serving as Professor of Medicine at Harvard Medical School and Senior Investigator at the Joslin Diabetes Center, Dr. Kulkarni brings invaluable strategic insight from his extensive experience with global pharmaceutical companies, guiding Hummsa Biotech through complex drug development pathways and regulatory landscapes.
Director, Institute for Diabetes and Obesity, Helmholtz Munich; Full Professor, Ludwig-Maximilians-University Munich (LMU)
Dr. Timo Müller is a distinguished scientist in obesity and diabetes pharmacology, internationally recognized for his groundbreaking work on unimolecular polyagonists targeting GLP-1, GIP, and Glucagon receptors.
As a key member of the international team that developed these next-generation therapeutics, his research has fundamentally advanced our understanding of multi-receptor approaches to metabolic disease treatment.
His studies reveal novel mechanisms of drug action in the brain and have established the foundation for selectively targeted GIP system therapies. Dr. Müller's expertise in pharmacological concepts and drug development strategies directly supports Hummsa Biotech's development of sophisticated metabolic therapeutics.
His exceptional contributions have earned prestigious recognition including the Galenus-von-Pergamon Award, the Werner Creutzfeldt Award, and the EASD Minkowski Award, positioning him as one of the foremost authorities in metabolic syndrome and diabetes research.
Contact us
Phone
